Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Longitudinal Population-based Observational Study of COVID-19 in the UK Population (COVIDENCE UK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04330599
Recruitment Status : Recruiting
First Posted : April 1, 2020
Last Update Posted : October 30, 2020
Sponsor:
Collaborators:
King's College London
London School of Hygiene and Tropical Medicine
University of Edinburgh
Swansea University
Queen's University, Belfast
Barts & The London NHS Trust
Information provided by (Responsible Party):
Queen Mary University of London

Brief Summary:

COVIDENCE UK is a population-based observational longitudinal study that has the following objectives:

  1. To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population
  2. To characterise the natural history of COVID-19 in the UK population
  3. To evaluate the impact of COVID-19 on the physical and mental health of the UK population
  4. To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in COVIDENCE as comparison or control data for trial participants who have been randomised to receive one or more interventions.

Condition or disease
COVID-19

Layout table for study information
Study Type : Observational
Estimated Enrollment : 12000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Longitudinal Population-based Observational Study of COVID-19 in the UK Population
Actual Study Start Date : May 1, 2020
Estimated Primary Completion Date : April 1, 2025
Estimated Study Completion Date : April 1, 2025



Primary Outcome Measures :
  1. Incidence of confirmed COVID-19 [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Incidence of probable or suspected COVID-19 [ Time Frame: 5 years ]
  2. Incidence of COVID-19 requiring hospitalisation [ Time Frame: 5 years ]
  3. Incidence of COVID-19 requiring ventilatory support [ Time Frame: 5 years ]
  4. Incidence of fatal COVID-19 [ Time Frame: 5 years ]
  5. Symptom duration per COVID-19 episode [ Time Frame: 5 years ]
  6. Symptom severity per COVID-19 episode [ Time Frame: 5 years ]
  7. Incidence of seroconversion to SARS-CoV-2 [ Time Frame: 5 years ]
  8. Incidence of recurrent COVID-19 [ Time Frame: 5 years ]
  9. EQ-5D-3L health-related quality of life score [ Time Frame: 5 years ]
  10. Health care costs associated with incident COVID-19 [ Time Frame: 5 years ]
  11. Impact of the COVID-19 pandemic and the societal response on participants' financial status [ Time Frame: 5 years ]
  12. Incidence of COVID-19 on participant's physical health [ Time Frame: 5 years ]
  13. Impact of COVID-19 on participants' mental health [ Time Frame: 5 years ]
  14. Impact of COVID-19 on physical health of offspring born to participants during follow-up [ Time Frame: 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
UK residents aged 16 years or more
Criteria

Inclusion Criteria:

  • UK resident
  • Age ≥16 years

Exclusion Criteria: none


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04330599


Contacts
Layout table for location contacts
Contact: Adrian Martineau, PhD +442078822551 a.martineau@qmul.ac.uk
Contact: Hayley Holt, MSc h.holt@qmul.ac.uk

Locations
Layout table for location information
United Kingdom
Queen Mary University of London Recruiting
London, County (optional), United Kingdom, E1 2AB
Contact: Adrian R Martineau, MD PhD    02078822551    a.martineau@qmul.ac.uk   
Sponsors and Collaborators
Queen Mary University of London
King's College London
London School of Hygiene and Tropical Medicine
University of Edinburgh
Swansea University
Queen's University, Belfast
Barts & The London NHS Trust
Layout table for additonal information
Responsible Party: Queen Mary University of London
ClinicalTrials.gov Identifier: NCT04330599    
Other Study ID Numbers: COVIDENCE UK
First Posted: April 1, 2020    Key Record Dates
Last Update Posted: October 30, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases